We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Green Wallet (GW) aims to promote conscious spending by allowing users to buy sustainable products and earn rewards in the process from its app-based marketplace. GW gives users £5 free in green coins upon registering on the portal. Users also earn 1 green coin for every £1 they spend and 2 green coins for advocating for their favourite shops and sharing products on Instagram based on the number of likes or comments their posts receive. GW has also launched a bio-degradable debit card. The company has onboarded 4000+ social media followers, hosted 100 merchants with 1500+ products on its platform, and hit the target of 1,000 early user signups in its closed beta round. They intend to onboard up to 25,000 users and plant up to 250,000 trees in 2021. GW will use the investment to boost merchant outreach, promote marketing initiatives, acquire key personnel across departments, and optimise infrastructure and compliance regularities.
days to go: Expired investment: £261,770
OvuSense is a women's health monitoring platform offering continuous insights into the reproductive cycle. With over 45,000 users and 10 patents, they aim to expand through partnerships, starting with a large IVF clinic chain. Addressing underdiagnosed health issues, their platform provides accurate cycle monitoring, health screening, and treatment tracking. Backed by institutional investors, OvuSense stands out for its predictive capabilities and accuracy in ovulation tracking, empowering women's fertility control.
days to go: Expired investment: £169,920
Patch is a modern plant shop for contemporary plant people. It helps in finding the most suitable plants and delivering them to the door. The company has delivered over 2,50,000 plants to over 82,000 customers in Paris and London. Patch has witnessed solid growth at +124% vs last year, reaching £4.48m in revenue. The company has a 4.6-star rating on TrustPilot and, it has been featured in The Times, The Telegraph etc. The funds will be used to expand across Europe, eliminate the middle-man and expand into the B2B market.

Pitch Rated

68%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £2,412,150
Infobode is a members-only online platform that is revolutionising the real estate industry by providing easy access to information. Infabode streamlined hundreds of prestigious content partners into a single platform, customised for each user. This company was officially launched in March 2016. Although, it was founded in 2014 but still it remained in a beta-mode for the next two years for building a prototype and talking to potential content providers. Furthermore, Infobode has convinced 10 content providers such as Knight Frank, JLL, and Cushman & Wakefield to share their market views and research through the platform in exchange for an increased market range. By 2018, the company had around 420 content providers who were sharing their research and facts to a network of 17000 global members. With the proceeds, Infobode is planning to hire marketing professionals as well as a marketing budget.
days to go: Expired investment: £120,568
Multiple brokers and clients can connect with each other on the only FCA-regulated social trading app. Pelican's platform is designed for traders to discuss strategies and share, copy, oppose or execute trades similarly to traditional traders on Bloomberg terminals. Revenue is generated via client-trading rebates and subscriptions from users following good traders and mentors. Further B2B revenue streams include set-up and monthly service fees.
days to go: Expired investment: £465,209
Gendius' has created intellin, an application through which people can track diabetes and make a good decision to reduce the risk of diabetes. It is on a mission to make sure that every person with diabetes knows their risk of complications and how to control them. The company has been launched across the EU with over 3,500 downloads in the EU and UK. In 2018, the company won £25K Momentum award to complete UX/UI research and, it has passed ISO27001. Recently, it has been invited to HIMSSHealth2.0 conference for the application's live demo.
days to go: Expired investment: £518,630
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph